OBI-992 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial

1.Date of occurrence of the event:2024/01/03 2.New drug name or code: OBI-992 TROP2 ADC 3.Indication: OBI-992 is an antibody drug conjugate (ADC) for cancer treatment that is based on TROP2 to target cancer cells. ADC releases a small molecule payload through the specificity of the antibody and directly deploys cytotoxic molecule at the targeted cancer […]

This article is password protected.

To view the content, please enter your password in the field below